AR127270A1 - Formulación de anticuerpos anti-cd47 - Google Patents
Formulación de anticuerpos anti-cd47Info
- Publication number
- AR127270A1 AR127270A1 ARP220102707A ARP220102707A AR127270A1 AR 127270 A1 AR127270 A1 AR 127270A1 AR P220102707 A ARP220102707 A AR P220102707A AR P220102707 A ARP220102707 A AR P220102707A AR 127270 A1 AR127270 A1 AR 127270A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody
- formulation
- seq
- amino acid
- acid sequence
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se relaciona con una formulación de anticuerpos anti-CD47, un método de preparación de la misma y su uso. Reivindicación 1: Una formulación farmacéutica estable, que comprende: (i) un anticuerpo anti-CD47 o un fragmento de unión a antígeno del mismo; (ii) un buffer; (iii) un estabilizante; y (iv) un surfactante, con un pH de aproximadamente 5,0 a aproximadamente 8,5, y en donde el anticuerpo anti-CD47 o del fragmento de unión a antígeno del mismo comprende (1) de uno a tres seleccionados entre HCDR1, HCDR2 y HCDR3 de una región variable de cadena pesada (VH), en donde VH comprende la secuencia de aminoácidos como se establece en SEQ ID Nº 1, 3, 5, 6 o 7; y/o (2) de uno a tres seleccionados entre LCDR1, LCDR2 y LCDR3 de una región variable de cadena liviana (VL), en donde la VL comprende la secuencia de aminoácidos como se establece en SEQ ID Nº 2, 4, 8, 9 o 10.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111179057 | 2021-10-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR127270A1 true AR127270A1 (es) | 2024-01-03 |
Family
ID=85803938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220102707A AR127270A1 (es) | 2021-10-09 | 2022-10-06 | Formulación de anticuerpos anti-cd47 |
Country Status (4)
| Country | Link |
|---|---|
| CN (1) | CN118234509A (es) |
| AR (1) | AR127270A1 (es) |
| TW (1) | TW202330027A (es) |
| WO (1) | WO2023056971A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202140565A (zh) * | 2020-04-10 | 2021-11-01 | 大陸商和記黃埔醫藥（上海）有限公司 | 抗ｃｄ４７抗體及其用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3789038T3 (da) * | 2010-05-14 | 2022-10-17 | Univ Leland Stanford Junior | Humaniserede og kimære monoklonale antistoffer mod cd47 |
| WO2018075857A1 (en) * | 2016-10-20 | 2018-04-26 | I-Mab | Novel cd47 monoclonal antibodies and uses thereof |
| CN108503708B (zh) * | 2017-09-01 | 2021-07-30 | 北京智仁美博生物科技有限公司 | 抗人cd47抗体及其用途 |
| AR113862A1 (es) * | 2017-12-01 | 2020-06-17 | Seattle Genetics Inc | Anticuerpos anti-cd47 y sus usos para tratar cáncer |
| CN110538321B (zh) * | 2018-05-29 | 2023-03-10 | 江苏恒瑞医药股份有限公司 | 一种cd47抗体药物组合物及其用途 |
| TWI764097B (zh) * | 2019-02-26 | 2022-05-11 | 大陸商信達生物製藥（蘇州）有限公司 | 包含抗ｃｄ４７抗體的製劑及其製備方法和用途 |
| MX2022006578A (es) * | 2019-12-17 | 2022-07-04 | Pfizer | Anticuerpos especificos para cd47, pd-l1 y sus usos. |
-
2022
- 2022-10-06 AR ARP220102707A patent/AR127270A1/es unknown
- 2022-10-07 TW TW111138267A patent/TW202330027A/zh unknown
- 2022-10-09 CN CN202280067878.XA patent/CN118234509A/zh active Pending
- 2022-10-09 WO PCT/CN2022/124085 patent/WO2023056971A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN118234509A (zh) | 2024-06-21 |
| WO2023056971A1 (en) | 2023-04-13 |
| TW202330027A (zh) | 2023-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
| PE20210132A1 (es) | Anticuerpos anti-cd3 y usos de estos | |
| PE20181921A1 (es) | NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS | |
| PE20130226A1 (es) | Anticuerpos hacia gdf8 humano | |
| AR100573A1 (es) | Anticuerpos anti-il-17, un método para producirlos y utilizarlos | |
| CO6230999A2 (es) | Anticuerpo anti-esclerostina | |
| PE20210045A1 (es) | Anticuerpos agonistas contra pd-1 y usos de estos | |
| AR110017A1 (es) | Anticuerpos de pd-1 y usos de estos | |
| PE20181326A1 (es) | Anticuerpos que se unen especificamente a pd-1 y sus usos | |
| PE20130817A1 (es) | Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos | |
| PE20212088A1 (es) | Anticuerpos anti-tau y uso de los mismos | |
| PE20190630A1 (es) | Anticuerpos de anti-tim-3 | |
| PE20180604A1 (es) | Anticuerpos pd-l1 (que se unen al ligando 1 de muerte celular programada 1 humana) | |
| PE20220218A1 (es) | Conjugados de anticuerpo-farmaco inhibidores de mcl-1 y sus metodos de uso | |
| RS54111B1 (en) | ANTI-ALPHA 2 INTEGRIN ANTIBODIES AND THEIR USES | |
| PE20121360A1 (es) | Anticuerpos neutralizadores contra el receptor de prolactina | |
| AR104906A1 (es) | Anticuerpos dirigidos a la proteína morfogenética ósea 9 (bmp9) y métodos a partir de estos | |
| AR123480A1 (es) | Moléculas de unión terapéuticas | |
| AR110967A1 (es) | Anticuerpos miméticos fgf21 y su uso | |
| ZA202211457B (en) | Anti-cd73 antibody and use thereof | |
| AR092325A1 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit | |
| AR127270A1 (es) | Formulación de anticuerpos anti-cd47 | |
| AR123912A2 (es) | ANTICUERPOS QUE SE UNEN A TGF-a Y EPIREGULINA | |
| PE20240363A1 (es) | Anticuerpos anti-ccr8 y usos de los mismos | |
| AR127273A1 (es) | Anticuerpos biespecíficos que se unen específicamente a cd47 y her2 y usos de los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |